Nuclera Launches Antibody Triage Service to Advance AI-Driven Antibody Discovery

Why It Matters

By providing rapid, cost‑effective validation of AI‑generated candidates, the service shortens discovery timelines and improves R&D efficiency, a critical advantage in the competitive biologics market.

Key Takeaways

• Nuclera offers 96‑plex cell‑free expression for rapid antibody triage
• Service converts AI‑generated libraries into experimental binding data early
• Early binder identification cuts downstream expression costs by up to 50%
• Series C extension funds service rollout, total funding $87 M
• SPR kinetics added for decision‑grade validation of prioritized hits

Pulse Analysis

The integration of artificial intelligence and machine learning into antibody design has exploded over the past few years, enabling researchers to generate millions of virtual candidates in silico. While computational methods can predict affinity and developability, the industry still grapples with the experimental bottleneck of confirming which molecules truly bind their targets. Traditional secondary‑screening workflows rely on labor‑intensive mammalian expression and isolated assays, inflating both time and cost. As a result, many promising AI‑derived hits are abandoned before reaching preclinical stages, limiting the return on computational investment.

Nuclera’s new antibody‑screening service tackles this gap with a high‑throughput, 96‑plex cell‑free expression platform that can produce full‑length antibodies in a matter of hours. The parallel expression is coupled to binary binding assays, rapidly filtering large libraries down to a focused set of confirmed binders. Those hits then undergo surface plasmon resonance analysis to deliver kinetic parameters that are decision‑grade for lead selection. By delivering experimental binding data early, the workflow eliminates non‑binders before costly mammalian scale‑up, potentially cutting downstream expression expenses by as much as half.

The timing aligns with Nuclera’s recent Series C extension, which brings total financing to $87 million and signals investor confidence in AI‑enabled biologics platforms. As pharmaceutical companies and biotech startups race to shorten discovery cycles, services that de‑risk early‑stage candidates are likely to become standard components of R&D pipelines. Competitors such as AbCellera and Distributed Bio are also building high‑throughput screening capabilities, but Nuclera’s cell‑free approach offers a faster, lower‑cost alternative to conventional expression systems. If widely adopted, the service could reshape how the industry validates AI‑generated antibodies, accelerating the path from concept to clinic.